Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Head and Neck Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 35 articles:
HTML format
Text format



Single Articles


    October 2017
  1. WERNER RA, Schmid JS, Higuchi T, Javadi MS, et al
    Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib.
    J Nucl Med. 2017 Oct 12. pii: jnumed.117.199778. doi: 10.2967/jnumed.117.199778.
    PubMed     Text format     Abstract available


    September 2017
  2. ROHDE M, Nielsen AL, Pareek M, Johansen J, et al
    A PET/CT-based strategy is a stronger predictor of survival than a standard imaging strategy in patients with head and neck squamous cell carcinoma.
    J Nucl Med. 2017 Sep 1. pii: jnumed.117.197350. doi: 10.2967/jnumed.117.197350.
    PubMed     Text format     Abstract available


    June 2017
  3. O'DONOGHUE JA, Lewis JS, Pandit-Taskar N, Fleming SE, et al
    Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.194555. doi: 10.2967/jnumed.117.194555.
    PubMed     Text format     Abstract available


  4. NA KJ, Choi H
    Tumor metabolic features identified by FDG PET correlates with gene networks of immune cell microenvironment in head and neck cancer.
    J Nucl Med. 2017 Jun 6. pii: jnumed.117.194217. doi: 10.2967/jnumed.117.194217.
    PubMed     Text format     Abstract available


  5. ROHDE M, Nielsen AL, Johansen J, Sorensen JA, et al
    Head-to-head comparison of chest x-ray/head and neck MRI, chest CT/head and neck MRI, and 18F-FDG-PET/CT for detection of distant metastases and synchronous cancer in oral, pharyngeal, and laryngeal Cancer.
    J Nucl Med. 2017 Jun 1. pii: jnumed.117.189704. doi: 10.2967/jnumed.117.189704.
    PubMed     Text format     Abstract available


    April 2017
  6. NICHOLS KJ, Robeson W, Yoshida-Hay M, Zanzonico PB, et al
    Alternative Means of Estimating 131I Maximum Permissible Activity to Treat Thyroid Cancer.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.192278. doi: 10.2967/jnumed.117.192278.
    PubMed     Text format     Abstract available


  7. O' DOHERTY J, Jauregui-Osoro M, Brothwood T, Szyszko T, et al
    18F-tetrafluoroborate (18F-TFB), a PET probe for imaging sodium-iodide symporter expression: Whole-body biodistribution, safety and radiation dosimetry in thyroid cancer patients.
    J Nucl Med. 2017 Apr 6. pii: jnumed.117.192252. doi: 10.2967/jnumed.117.192252.
    PubMed     Text format     Abstract available


    February 2017
  8. GRKOVSKI M, Schoder H, Lee N, Carlin SD, et al
    Multiparametric imaging of tumor hypoxia and perfusion with 18F-FMISO dynamic PET in head and neck cancer.
    J Nucl Med. 2017 Feb 9. pii: jnumed.116.188649. doi: 10.2967/jnumed.116.188649.
    PubMed     Text format     Abstract available


    January 2017
  9. PLYKU D, Hobbs RF, Huang K, Atkins F, et al
    Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer.
    J Nucl Med. 2017 Jan 19. pii: jnumed.116.179366. doi: 10.2967/jnumed.116.179366.
    PubMed     Text format     Abstract available


  10. LAFFON E, Thumerel M, Jougon J, Marthan R, et al
    Cumulated activity Comparison of 64Cu-/177Lu-labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
    J Nucl Med. 2017 Jan 12. pii: jnumed.116.180521. doi: 10.2967/jnumed.116.180521.
    PubMed     Text format     Abstract available


    October 2016
  11. BEUKINGA J, Hulshoff JB, Dijk LV, Muijs C, et al
    Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer with textural features derived from pre-treatment 18F-FDG PET/CT imaging.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.180299.
    PubMed     Text format     Abstract available


  12. DEANDREIS D, Rubino C, Tala H, Leboulleux S, et al
    Comparison Of Empiric Versus Whole Body/Blood Clearance Dosimetry-Based Approach To Radioactive Iodine Treatment In Patients With Metastases From Differentiated Thyroid Cancer.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.179606.
    PubMed     Text format     Abstract available


    September 2016
  13. FINDLAY JM, Bradley KM, Wang LM, Franklin JM, et al
    PREDICTING PATHOLOGICAL RESPONSE OF ESOPHAGEAL CANCER TO NEOADJUVANT CHEMOTHERAPY: THE IMPLICATIONS OF METABOLIC NODAL RESPONSE FOR PERSONALISED THERAPY.
    J Nucl Med. 2016 Sep 15. pii: jnumed.116.176313.
    PubMed     Text format     Abstract available


  14. RASMUSSEN JH, Norgaard M, Hansen AE, Vogelius IR, et al
    Feasibility of Multiparametric Imaging with PET/MR in Head and Neck Squamous Cell Carcinoma.
    J Nucl Med. 2016 Sep 8. pii: jnumed.116.180091.
    PubMed     Text format     Abstract available


  15. MOORE LS, Rosenthal EL, Chung TK, de Boer E, et al
    Characterizing the utilities and limitations of repurposing an open-field optical imaging device for fluorescence-guided surgery in head and neck cancer patients.
    J Nucl Med. 2016 Sep 1. pii: jnumed.115.171413.
    PubMed     Text format     Abstract available


    August 2016
  16. YANG X, Li J, Li X, Liang Z, et al
    TERT promoter mutation predicts radioiodine refractory in distant metastatic differentiated thyroid cancer.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.180240.
    PubMed     Text format     Abstract available


    July 2016
  17. WONG KH, Panek R, Welsh LC, Mcquaid D, et al
    The predictive value of early assessment after one cycle of induction chemotherapy with 18F-FDG-PET/CT and DW-MRI for response to radical chemoradiotherapy in head and neck squamous cell carcinoma.
    J Nucl Med. 2016 Jul 14. pii: jnumed.116.174433.
    PubMed     Text format     Abstract available


    June 2016
  18. KLEIN HESSELINK EN, Brouwers AH, de Jong JR, van der Horst-Schrivers AN, et al
    Effects of radioiodine treatment on salivary gland function in patients with differentiated thyroid carcinoma: a prospective study.
    J Nucl Med. 2016 Jun 23. pii: jnumed.115.169888.
    PubMed     Text format     Abstract available


    May 2016
  19. BODET-MILIN C, Faivre-Chauvet A, Carlier T, Rauscher A, et al
    Immuno-PET using anti-CEA bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a First-in Human trial.
    J Nucl Med. 2016 May 26. pii: jnumed.116.172221.
    PubMed     Text format     Abstract available


  20. JENTZEN W, Verschure F, van Zon A, van de Kolk R, et al
    Response Assessment of Bone Metastases from Differentiated Thyroid Cancer Patients in the Initial Radioiodine Treatment Using Iodine-124 PET Imaging.
    J Nucl Med. 2016 May 19. pii: jnumed.115.170571.
    PubMed     Text format     Abstract available


  21. RUHLMANN M, Jentzen W, Ruhlmann V, Pettinato C, et al
    High Level of Agreement between Pretherapeutic 124I PET and Intratherapeutic 131I Images in Detecting Iodine-positive Thyroid Cancer Metastases.
    J Nucl Med. 2016 May 5. pii: jnumed.115.169649.
    PubMed     Text format     Abstract available


    April 2016
  22. MUZI M, Krohn KA
    Imaging Hypoxia with (1)(8)F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis.
    J Nucl Med. 2016;57:497-8.
    PubMed     Text format    


    March 2016
  23. BINSE I, Poeppel TD, Ruhlmann M, Ezziddin S, et al
    68Ga-DOTATOC-PET/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin.
    J Nucl Med. 2016 Mar 31. pii: jnumed.115.171942.
    PubMed     Text format     Abstract available


    February 2016
  24. SONG IH, Lee TS, Park YS, Lee JS, et al
    Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
    J Nucl Med. 2016 Feb 25. pii: jnumed.115.167155.
    PubMed     Text format     Abstract available


  25. WIERTS R, Brans B, Havekes B, Kemerink G, et al
    Dose-response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
    J Nucl Med. 2016 Feb 25. pii: jnumed.115.168799.
    PubMed     Text format     Abstract available


  26. LIN CM, Yeh PT, Doyle P, Tsan YT, et al
    Association between 131I treatment for thyroid cancer and risk of receiving cataract surgery-a cohort study from Taiwan.
    J Nucl Med. 2016 Feb 2. pii: jnumed.115.167197.
    PubMed     Text format     Abstract available


    January 2016
  27. VAN ROSSUM PS, Fried DV, Zhang L, Hofstetter WL, et al
    The incremental value of subjective and quantitative assessment of 18F-FDG PET for the prediction of pathologic complete response to preoperative chemoradiotherapy in esophageal cancer.
    J Nucl Med. 2016 Jan 21. pii: jnumed.115.163766.
    PubMed     Text format     Abstract available


    December 2015
  28. LIN CY, Lin CL, Huang WS, Kao CH, et al
    Risk of Breast Cancer in Patients With Thyroid Cancer Receiving or Not Receiving I-131 Treatment: A Nationwide Population-based Cohort Study.
    J Nucl Med. 2015 Dec 30. pii: jnumed.115.164830.
    PubMed     Text format     Abstract available


    November 2015
  29. GRKOVSKI M, Schwartz J, Gonen M, Schoder H, et al
    Feasibility of 18F-fluoromisonidazole kinetic modeling in head and neck cancer using shortened acquisition times.
    J Nucl Med. 2015 Nov 25. pii: jnumed.115.160168.
    PubMed     Text format     Abstract available


  30. KIST JW, de Keizer B, van der Vlies M, Brouwers AH, et al
    124I PET/CT to predict the outcome of blind 131I treatment in patients with biochemical recurrence of differentiated thyroid cancer; results of a multicenter diagnostic cohort study (THYROPET).
    J Nucl Med. 2015 Nov 25. pii: jnumed.115.168138.
    PubMed     Text format     Abstract available


  31. LI F, Jorgensen JT, Forman J, Hansen AE, et al
    64Cu-ATSM reflects pO2 levels in human head and neck cancer xenografts but not in colorectal cancer xenografts.
    J Nucl Med. 2015 Nov 19. pii: jnumed.115.155663.
    PubMed     Text format     Abstract available


  32. JANSSEN I, Chen CC, Taieb D, Patronas NJ, et al
    68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared to other functional imaging modalities and CT/MRI.
    J Nucl Med. 2015 Nov 12. pii: jnumed.115.161018.
    PubMed     Text format     Abstract available


  33. EBERLEIN U, Scherthan H, Bluemel C, Peper M, et al
    DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients after Radioiodine Therapy.
    J Nucl Med. 2015 Nov 12. pii: jnumed.115.164814.
    PubMed     Text format     Abstract available


    September 2015
  34. SINGH TD, Jeong SY, Lee SW, Ha JH, et al
    Inverse agonist of estrogen-related receptor gamma (ERRgamma) enhances sodium iodide symporter function through mitogen-activated protein kinase signaling in anaplastic thyroid cancer cells.
    J Nucl Med. 2015 Sep 3. pii: jnumed.115.160366.
    PubMed     Text format     Abstract available


    August 2015
  35. RYU CH, Ryu J, Ryu YM, Lee YJ, et al
    Radioactive iodine therapy does not affect vocal function within one year after total thyroidectomy.
    J Nucl Med. 2015 Aug 13. pii: jnumed.115.161463.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: